Despite its relative low incidence, PDAC is one of the most aggressive and lethal types of cancer, being currently the seventh leading cause of cancer death worldwide, with a 5-year survival rate of 10.8%. Taking into consideration the necessity to improve the prognosis of these patients, this research has been focused on the discovery of new biomarkers. For this purpose, patients with BL and resectable disease were recruited. Serum cytokines and growth factors were monitored at different time points using protein arrays. Immune cell populations were determined by flow cytometry in peripheral blood as well as by immunohistochemistry (IHC) in tumor tissues. Several cytokines were found to be differentially expressed between the study subgrou...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvi...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
Purpose Novel biomarkers to better predict outcome and select the best therapeutic strategy for the ...
The interest in liquid biopsy is growing because it could represent a non-invasive prognostic or pre...
The interest in liquid biopsy is growing because it could represent a non-invasive prognostic or pre...
Background: Biomarkers predicting treatment response may be used to stratify patients with pancreati...
The overall survival of patients with pancreatic ductal adenocarcinoma is extremely low. Although ge...
Pancreatic Ductal Adenocarcinoma (PDAC) is a malignant neoplasm and is the fourth leading cause of c...
International audiencePDAC is one of the most heterogeneous cancers with low chemotherapeutic sensit...
Surgery is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (...
A systematic review of the role of cytokines in clinical medicine as diagnostic, prognostic, or pred...
This work aims to evaluate the initial values and changes of peripheral blood lymphocytes during tre...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant tumor. The immune profile of PDAC ...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvi...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvi...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
Purpose Novel biomarkers to better predict outcome and select the best therapeutic strategy for the ...
The interest in liquid biopsy is growing because it could represent a non-invasive prognostic or pre...
The interest in liquid biopsy is growing because it could represent a non-invasive prognostic or pre...
Background: Biomarkers predicting treatment response may be used to stratify patients with pancreati...
The overall survival of patients with pancreatic ductal adenocarcinoma is extremely low. Although ge...
Pancreatic Ductal Adenocarcinoma (PDAC) is a malignant neoplasm and is the fourth leading cause of c...
International audiencePDAC is one of the most heterogeneous cancers with low chemotherapeutic sensit...
Surgery is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (...
A systematic review of the role of cytokines in clinical medicine as diagnostic, prognostic, or pred...
This work aims to evaluate the initial values and changes of peripheral blood lymphocytes during tre...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant tumor. The immune profile of PDAC ...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvi...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvi...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...